Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Cardiovascular Outcomes in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Initiating SGLT2 or GLP-1 Medications within Federated-Real-World Data

Speaker(s)

Koonce R1, Constantino R2, Gressler L3
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2Defense Health Agency, San Antonio, TX, USA, 3University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Objective: Sodium-glucose cotransporter 2 inhibitors (SGLT2) and glucagon-like peptide 1 receptor agonists (GLP-1) have been found to potentially decrease adverse cardiovascular outcome risk in clinical trials. The objective of this manuscript is to use a federated, real-world data source to compare the cardiovascular benefits between these two medication classes in patients with Type 2 Diabetes (DM2) and established atherosclerotic cardiovascular disease (ASCVD).

Methods: Leveraging a global federated data research platform representing over 57 health care organizations, TriNetX Inc, we retrospectively analyzed two cohorts of DM2 patients with established ASCVD initiating either SGLT2 or GLP-1 medications. The primary outcome was a composite outcome of major adverse cardiovascular events (MACE) including cerebral infarction, acute myocardial infarction, acute coronary event, percutaneous coronary intervention, or coronary artery bypass grafting within 3 years following the initiation of an SGLT2 or GLP1 medication. The secondary outcome was all-cause mortality. Propensity score matching was employed to account for observed baseline confounders. The outcomes were estimated using logistic regression.

Results: The SGLT2 cohort consisted of 48,059 patients while the GLP-1 cohort consisted of 55,090 patients. 40,266 patients remained after propensity score matching (equal cohorts). The matched cohort had an average age of 66 years, were 68% white, and 57% male. The primary composite outcome showed no significant difference between groups [OR: 0.975, (95% CI: 0.942 thru 1.008)]. The GLP1 cohort was found to have higher odds of all-cause mortality compared to the SGLT-2 cohort [OR: 1.121, (95% CI: 1.053 thru 1.193)].

Conclusion: While no significant difference in cardiovascular events was observed, the finding of reduction of all-cause mortality among patient receiving SGLT2i indicates a potential clinical benefit among patients with both DM2 and ASCVD. Next steps should involve different subpopulations to determine which groups are most likely to benefit from selection of SGLT2 over GLP-1 medication classes.

Code

CO57

Topic

Clinical Outcomes, Real World Data & Information Systems

Topic Subcategory

Comparative Effectiveness or Efficacy, Distributed Data & Research Networks

Disease

Cardiovascular Disorders, Drugs